These studies demonstrate that CaMKI can control cell proliferation, migration, and survival in medulloblastoma, breast and haematopoietic cancers, and therefore, may be a potential anti-cancer target for these cancer types. This evidence concerns the gene CAMK1 and medulloblastoma.